pranlukast

Pranlukast (ONO-1078) is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Pranlukast hemihydrate (ONO-1078 hemihydrate) is a selective and potent leukotriene (LT) antagonist with anti-asthmatic activity that inhibits [3H]LTD4 and [3H]LTE4 binding to lung membranes and antagonizes LTC4-induced constriction of guinea-pig airways.Pranlukast hemihydrate is used in the study of asthma. Pranlukast hemihydrate is used in the study of asthma.

CP-199331, a cysLT1 receptor antagonist, demonstrates equivalent potency to commercially available cysLT1 receptor antagonists zafirlukast and pranlukast. It shows favorable pharmacokinetic properties in both rats and monkeys, and unlike CP-85,958, no hepatotoxicity has been observed in monkeys.

Ieramilimab (LAG525) is a humanized antibody targeting LAG-3 with potential anticancer activity, blocking its interaction with MHC-II molecules by binding to LAG-3.Pranlukast hemihydrate can be used to study malignant tumors.